Is that liver cancer? Sometimes it’s good to rise.

As a liver surgeon, patients with an AFP rise are often encountered in routine outpatient consultations, and these patients are often very nervous to ask, “Doctor, what should I do, am I getting liver cancer?” In this regard, it is important to share with you the clinical significance of the elevated proteins of the lower fetal. AFP is an embryonic antigen tumour marker that is separated from the fetal serum and is a glucose protein produced during pregnancy by the fetus liver and egg yogurt. In the foetus, synthesis began in about six weeks, peaking in 12-15 months and decreasing in 18 months. Normal adult seroprotein is below 20 mg/L.And under what circumstances does the AFP rise? The AFP rise is divided into an increase in physiology and a rise in pathological rationality.AFP ‘ s increased physiology can be seen in the following:Infants: AFPs will increase significantly to a normal level in about one year of life.Pregnant women: AFP runs through placenta barriers from fetal to maternal blood, which is known as “mother-cares”. At the end of the three months of pregnancy, the peak was reached and then gradually decreased, and the post-natal period was rapidly reduced and normalized. So does the AFP for pregnant women increase indefinitely? Of course not! For pregnant women, the AFP rise will not normally exceed 400 μg/L or, if more than 400 μg/L, the pathological rise will have to be considered.The rational rise of the AFP is reflected in:1. Hepatic cancer: AFP is the most commonly used sign of liver cancer, with about 70 per cent of liver cancer patients having an increase in the number of fetal proteins in their serum, with a high degree of specificity and sensitivity, which can be used to monitor the recurrence of liver cancer and its therapeutic efficacy. However, not all liver cancer patients will rise, and about 20-30 per cent of young liver cancer patients will remain at normal levels and even some liver cancer patients will remain normal from the onset to the end of the disease. As a result, the AFP is normal and has no liver cancer; similarly, the AFP increases liver cancer.2. Tumours in other areas: AFP rises are also observed in other areas, such as liver transfer tumors, testicular tumours, ovarian tumours, intestinal cancer, pancreas cancer and stomach cancer.3. Hepatitis campaign period: AFP does not only increase tumours. Hepatitis due to various causes, including viral hepatitis, fatty hepatitis, drug hepatitis damage, alcohol hepatitis, among others, can cause an increase in foetal proteins, or more than 10 times higher, which is expected to decrease as liver conditions improve. For patients with liver failure, the increase in the AFP is good, suggesting that there is a large number of dead liver cells regenerative, which can be an important indicator of the prognosis of liver failure.4. Hepatic cirrhosis: Most liver cancer patients have a liver cirrhosis base, and clinically, hepatic cirrhosis and early cancer cirrhosis are actually difficult to identify. The liver cirrhosis patients themselves can rise, usually in the range of 20-200 mg/L, and then decline after two months, most of them not more than two months. If AFP undergoes sexual increase (over 400 μg/L), it is necessary to be alert to liver cancer.5. Genetic defects in the foetus during pregnancy: An abnormal increase in the AFP can occur in cases of abdominal deformation, umbilical growth, or neural defects.Placental implants in the late stages of pregnancy: Placental implants can destroy the mother-to-child barrier and allow the fetus AFP to enter the mother-to-child through the placenta barrier, raising the mother-to-child AFP five or ten times the normal population.Overall, most AFP increases occur in liver cancer, but tumours can rise in other areas. AFP rise can be seen in normal physiology, as well as in non-tumour diseases, and liver cancer is considered to be the result of no AFP rise. In the case of patients with abnormally high AFPs, diagnosis needs to be facilitated in conjunction with other examinations, and it is not possible to generalize on the basis of the degree of rise and dynamic changes. Primary liver cancer